secwatch.observer — SEC 8-K summary
======================================

Issuer:     Contineum Therapeutics, Inc. (CTNM)
CIK:        0001855175
Form:       8-K
Filed at:   2026-01-26T23:59:59+00:00
Accession:  0001437749-26-002072
Event type: other_material
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Contineum Therapeutics approves 2026 Inducement Plan with 750,000 share reserve
-------------------------------------------------------------------------------

- Board approved 2026 Employment Inducement Equity Incentive Plan on January 23, 2026.
- Plan reserves 750,000 shares of Class A common stock for awards to new employees as inducement material.
- Adopted without stockholder approval under Nasdaq Rule 5635(c)(4); no incentive stock options allowed.
- Substantially similar to existing 2024 Equity Incentive Plan except for ISO prohibition and eligible recipients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855175/000143774926002072/0001437749-26-002072-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855175/000143774926002072/ctnm20260121_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-002072

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer